Jun 30, 2021 / 04:00PM GMT
Operator
Hello, everyone, and welcome to Entera Bio's Investor Conference Call today to discuss the company's results from the successfully concluded Phase II clinical trial of its drug candidate EB613 for the treatment of osteoporosis.
Joining us on the call today are Dr. Liana Tripto-Shkolnik, an osteoporosis expert and principal investigator of Entera's Phase II study, and Entera's executive management team, including CEO, Spiros Jamas; Phillip Schwartz, the President of R&D; Art Santora, the Chief Medical Officer; and U.S.-based CFO, Ramesh Ratan.
Spiros Jamas will open the call with an overview of the Phase II results, followed by Dr. Tripto-Shkolnik, who will provide context on the results of the study and the significance of an oral drug to treat osteoporosis.
(Operator Instructions) Please be advised that today's may be recorded. (Operator Instructions)
I will now turn the call over to Ramesh Ratan for the safe harbor statement.
Ramesh Ratan - Entera Bio Ltd. - U.S. CFO
On our call this morning, we will share with you
Entera Bio Ltd to Discuss Phase 2 Results for EB613 Call Transcript
Jun 30, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers